CROSSJECT Publishes 2024 Financial Results

CROSSJECT, a specialty pharmaceutical company, reported significant advancements in 2024. The company focused on ZEPIZURE®, a potential emergency treatment for epileptic seizures, planning to file with the FDA by mid-2026. The collaboration with Eurofins Scientific is critical in reaching this milestone.

Financially, CROSSJECT's cash position rose to €7 million by year-end, compared to €2 million in 2023. Operating income remained stable at €13.3 million, while operating expenses grew by 4% to €26.2 million. In 2024, the net loss increased to €12.8 million from €8.6 million the previous year. Funding efforts continued through partnerships and government grants.

Progress was also made with partnerships, notably with Eton Pharmaceuticals for ZENEO® Hydrocortisone. Tony Tipton's recruitment as COO USA underlines CROSSJECT's commitment to bolster its US market presence.